Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children

Vaccine

Volumn 33, Issue 38, 2015, Pages 4790-4797

  Curtis, Donna ^a   Ning, Mariangeli F ^a   Armon, Carl ^b   Li, Shaobing ^a   Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Children; HIV; Immunogenicity; Influenza infection; Influenza vaccine; LAIV4; Safety

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; VIRUS RNA; LIVE VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA VIRUS; MALE; MYALGIA; NOSE OBSTRUCTION; NOSE SMEAR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHINORRHEA; SEASONAL INFLUENZA; SORE THROAT; VACCINATION REACTION; VIRUS SHEDDING; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; NASOPHARYNX; ORTHOMYXOVIRIDAE; PATHOLOGY; PRESCHOOL CHILD; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN A; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NASOPHARYNX; ORTHOMYXOVIRIDAE; POLYMERASE CHAIN REACTION; VACCINES, ATTENUATED; VIRUS SHEDDING; YOUNG ADULT;

EID: 84940725117     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.082     Document Type: Article

References (32)

1. Sasaki S., Jaimes M.C., Holmes T.H., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81(1):215-228.
2. Hoft D.F., Babusis E., Worku S., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011, 204(6):845-853.
3. Talbot T.R., Crocker D.D., Peters J., et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005, 26(5):494-500.
4. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181(3):1133-1137.
5. Sasaki S., He X.S., Holmes T.H., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3(8):e2975.
6. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011, 5(2):67-75.
7. Ambrose C.S., Wu X., Knuf M., Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012, 30(5):886-892.
8. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(1):36-44.
9. Ashkenazi S., Vertruyen A., Aristegui J., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25(10):870-879.
10. Fleming D.M., Crovari P., Wahn U., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25(10):860-869.
11. Piedra P.A., Gaglani M.J., Kozinetz C.A., et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007, 120(3):e553-e564.
12. Belshe R.B., Toback S.L., Yi T., Ambrose C.S. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses 2010, 4(3):141-145.
13. Pass R.F., Nachman S., Flynn P.M., et al. Immunogenicity of licensed influenza A (H1N1) 2009 monovalent vaccines in HIV-infected children and youth. J Pediatr Infect Dis Soc 2013, 2(4):352-360.
14. Flynn P.M., Nachman S., Muresan P., et al. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis 2012, 206(3):421-430.
15. Tiu C.T., Lin Y.S., Pagala M., et al. Antibody response to inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with and without HIV. J Acquir Immune Defic Syndr 2011, 58(3):e99-e102.
16. Kosalaraksa P., Srirompotong U., Newman R.W., Lumbiganon P., Wood J.M. Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine 2011, 29(16):3055-3060.
17. Madhi S.A., Dittmer S., Kuwanda L., et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS 2013, 27(3):369-379.
18. Halasa N., Englund J.A., Nachman S., et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011, 29(24):4110-4115.
19. Carr S., Allison K.J., Van De Velde L.A., et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011, 204(10):1475-1482.
20. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(20):1405-1412.
21. Tam J.S., Capeding M.R., Lum L.C., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26(7):619-628.
22. Vesikari T., Fleming D.M., Aristegui J.F., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118(6):2298-2312.
23. Levin M.J., Song L.Y., Fenton T., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26(33):4210-4217.
24. King J.C., Fast P.E., Zangwill K.M., et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20(12):1124-1131.
25. Weinberg A., Song L.Y., Walker R., et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010, 55(2):189-196.
26. Block S.L., Falloon J., Hirschfield J.A., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31(7):745-751.
27. King J.C., Treanor J., Fast P.E., et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181(2):725-728.
28. Mallory R.M., Malkin E., Ambrose C.S., et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 2010, 5(10):e13755.
29. Ambrose C.S., Wu X., Jones T., Mallory R.M. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012, 30(48):6794-6801.
30. Abzug M.J., Nachman S.A., Muresan P., et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 2013, 56(10):1488-1497.
31. Madhi S.A., Cutland C.L., Kuwanda L., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371(10):918-931.
32. Fiore A.E., Fry A., Shay D., et al. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60(1):1-24.